Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

01. Oktober 2025 09:30 ET | Quelle: Cellphire Therapeutics

Cellphire Therapeutics announces CRYPTICS Phase 2/3 Clinical Study Final Topline Results

CRYPTICS study met the primary efficacy endpoint measure, 24-hour chest tube drainage (Difference in LS Means was 142.0 mL; 95.576% confidence interval of volume difference lower than noninferiority...
22. April 2025 08:00 ET | Quelle: Cellphire Therapeutics

Cellphire Therapeutics Announces CRYPTICS Phase 2/3 Clinical Study Stopped Early for Efficacy Following Pre-Planned Interim Analysis by Independent Data Monitoring Committee (IDMC)

CRYPTICS study met the primary efficacy endpoint to demonstrate statistical non-inferiority of the cryopreserved CLPH-511 platelet product to the standard of care room temperature control platelet...
17. März 2025 10:00 ET | Quelle: Cellphire Therapeutics

Cellphire Therapeutics CLPH-511 Fast Track Designation Granted

ROCKVILLE, Md., March 17, 2025 (GLOBE NEWSWIRE) -- Cellphire Therapeutics, Inc., a clinical stage biotechnology company developing next-generation allogeneic, platelet-derived, cellular...